Effects of Intensive BP Control in CKD

Abstract
The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespecified subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial. We randomly assigned participants to a systolic BP target of <120 mm Hg (intensive group; n=1330) or <140 mm Hg (standard group; n=1316). After a median follow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD participants (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.63 to 1.05). The intensive group also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ between participants with and without CKD (P values for interactions ≥0.30). The prespecified main kidney outcome, defined as the composite of ≥50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6 months, the intensive group had a slightly higher rate of change in eGFR (−0.47 versus −0.32 ml/min per 1.73 m2 per year; P<0.03). The overall rate of serious adverse events did not differ between treatment groups, although some specific adverse events occurred more often in the intensive group. Thus, among patients with CKD and hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140 mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.
- blood pressure
- chronic kidney disease
- cardiovascular disease
- glomerular filtration rate
- hypertension
- mortality
- Copyright © 2017 by the American Society of Nephrology
In this issue
Jump to section
More in this TOC Section
Cited By...
- Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria
- BP in Young Adults with CKD and Associations with Cardiovascular Events and Decline in Kidney Function
- Thinking Outside the Box: Novel Kidney Protective Strategies in Kidney Transplantation
- Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study
- Much to Fear about MUCH
- Improving Care for Patients after Hospitalization with AKI
- Intensive Blood Pressure Lowering Should Be the Goal for Most Individuals at High Risk of Cardiovascular Disease Irrespective of Albuminuria
- The Effects of Intensive Blood Pressure Lowering on Markers of Mineral Metabolism in Persons with CKD in SPRINT
- Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD
- Chronic kidney disease referrals from general practitioners pre- and post National Institute for Health and Care Excellence guidance 2014
- Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation
- Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT
- Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines
- PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT
- Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
- A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes
- Target Blood Pressure for Cardiovascular Disease Prevention in Patients with CKD
- Intensive Blood Pressure Targets and Kidney Disease
- Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death
- Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research
- BP Measurement in Clinical Practice: Time to SPRINT to Guideline-Recommended Protocols
- BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD
- BP Targets in CKD, Mortality, and SPRINT: What Have We Learned?